Excision BioTherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Excision BioTherapeutics's estimated annual revenue is currently $9.1M per year.
- Excision BioTherapeutics's estimated revenue per employee is $155,000
Employee Data
- Excision BioTherapeutics has 59 Employees.
- Excision BioTherapeutics grew their employee count by -13% last year.
Excision BioTherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Founder | Reveal Email/Phone |
2 | VP Preclinical R&D Previous: Temple University, School Medicine | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Director Regulatory Affairs | Reveal Email/Phone |
Excision BioTherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Excision BioTherapeutics?
Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
keywords:N/A
N/A
Total Funding
59
Number of Employees
$9.1M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Excision BioTherapeutics News
Excision Biotherapeutics, which is using Crispr/Cas9 to target, and hopefully cure, infectious diseases like HIV;; and Saliogen Therapeutics,...
Excision Biotherapeutics, which is using Crispr/Cas9 to target, and hopefully cure, infectious diseases like HIV;; and Saliogen Therapeutics,...
The study, led by Excision BioTherapeutics, began in January and is currently expected to end in March 2025. The clinical trial includes...
The study, led by Excision BioTherapeutics, began in January and is currently expected to end in March 2025. The clinical trial includes...
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 59 | -17% | N/A |
#2 | $7.5M | 59 | 18% | N/A |
#3 | $7.4M | 59 | -21% | N/A |
#4 | $14.3M | 59 | 7% | N/A |
#5 | $14.3M | 59 | 11% | N/A |